| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
GRIN Stock Overview
Grown Rogue International Inc., through its subsidiaries, engages in growing and selling cannabis products in the United States.
Grown Rogue International Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.09 |
| 52 Week High | CA$0.21 |
| 52 Week Low | CA$0.065 |
| Beta | 0.75 |
| 1 Month Change | 0% |
| 3 Month Change | 20.00% |
| 1 Year Change | -55.00% |
| 3 Year Change | -57.14% |
| 5 Year Change | n/a |
| Change since IPO | -68.97% |
Recent News & Updates
Does Grown Rogue International (CSE:GRIN) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
Shareholder Returns
| GRIN | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | -14.3% | -9.5% | -0.8% |
| 1Y | -55.0% | -73.1% | -5.0% |
Return vs Industry: GRIN exceeded the Canadian Pharmaceuticals industry which returned -73.1% over the past year.
Return vs Market: GRIN underperformed the Canadian Market which returned -5% over the past year.
Price Volatility
| GRIN volatility | |
|---|---|
| GRIN Average Weekly Movement | 17.8% |
| Pharmaceuticals Industry Average Movement | 12.3% |
| Market Average Movement | 10.1% |
| 10% most volatile stocks in CA Market | 17.4% |
| 10% least volatile stocks in CA Market | 4.4% |
Stable Share Price: GRIN is more volatile than 90% of Canadian stocks over the past 3 months, typically moving +/- 18% a week.
Volatility Over Time: GRIN's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | J. Strickler | https://www.grownrogue.com |
Grown Rogue International Inc., through its subsidiaries, engages in growing and selling cannabis products in the United States. It offers flower products, such as indicas, sativas, and hybrids; and edibles, vape cartridges, pre-rolls, or concentrates. The company sells its products through dispensaries.
Grown Rogue International Fundamentals Summary
| GRIN fundamental statistics | |
|---|---|
| Market Cap | US$11.89m |
| Earnings (TTM) | US$550.22k |
| Revenue (TTM) | US$15.22m |
21.6x
P/E Ratio0.8x
P/S RatioIs GRIN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GRIN income statement (TTM) | |
|---|---|
| Revenue | US$15.22m |
| Cost of Revenue | US$5.33m |
| Gross Profit | US$9.89m |
| Other Expenses | US$9.34m |
| Earnings | US$550.22k |
Last Reported Earnings
Apr 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.0032 |
| Gross Margin | 64.97% |
| Net Profit Margin | 3.61% |
| Debt/Equity Ratio | 39.2% |
How did GRIN perform over the long term?
See historical performance and comparisonValuation
Is GRIN undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio
Key Valuation Metric
Which metric is best to use when looking at relative valuation for GRIN?
Other financial metrics that can be useful for relative valuation.
| What is GRIN's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | US$11.89m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.1x |
| Enterprise Value/EBITDA | 4.3x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does GRIN's PE Ratio compare to its peers?
| GRIN PE Ratio vs Peers |
|---|
| Company | PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 13.3x | ||
AYUR Ayurcann Holdings | 30.3x | 138.3% | CA$12.1m |
J Lotus Ventures | 13.7x | n/a | CA$6.7m |
CXXI C21 Investments | 3x | n/a | CA$42.6m |
YOUR YourWay Cannabis Brands | 6x | n/a | CA$23.2m |
GRIN Grown Rogue International | 21.6x | n/a | CA$15.4m |
Price-To-Earnings vs Peers: GRIN is expensive based on its Price-To-Earnings Ratio (21.6x) compared to the peer average (13.3x).
Price to Earnings Ratio vs Industry
How does GRIN's PE Ratio compare vs other companies in the North American Pharmaceuticals Industry?
Price-To-Earnings vs Industry: GRIN is expensive based on its Price-To-Earnings Ratio (21.6x) compared to the Canadian Pharmaceuticals industry average (11.5x)
Price to Earnings Ratio vs Fair Ratio
What is GRIN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 21.6x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate GRIN's Price-To-Earnings Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of GRIN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate GRIN's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate GRIN's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate GRIN's PEG Ratio to determine if it is good value.
Discover undervalued companies
Future Growth
How is Grown Rogue International forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score
0/6Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
72.0%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Grown Rogue International has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Examine Grown Rogue International's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Grown Rogue International competitive advantages and company strategy can generally be found in its financial reports archived here.
Past Performance
How has Grown Rogue International performed over the past 5 years?
Past Performance Score
2/6Past Performance Score 2/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
29.0%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GRIN has a large one-off loss of $783.1K impacting its April 30 2022 financial results.
Growing Profit Margin: GRIN became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: GRIN has become profitable over the past 5 years, growing earnings by 29% per year.
Accelerating Growth: GRIN has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: GRIN has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (118.1%).
Return on Equity
High ROE: GRIN's Return on Equity (18.7%) is considered low.
Discover strong past performing companies
Financial Health
How is Grown Rogue International's financial position?
Financial Health Score
5/6Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage
Financial Position Analysis
Short Term Liabilities: GRIN's short term assets ($8.1M) exceed its short term liabilities ($5.5M).
Long Term Liabilities: GRIN's short term assets ($8.1M) exceed its long term liabilities ($3.3M).
Debt to Equity History and Analysis
Debt Level: GRIN's net debt to equity ratio (18.6%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if GRIN's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: GRIN's debt is well covered by operating cash flow (36.5%).
Interest Coverage: GRIN's interest payments on its debt are well covered by EBIT (3.7x coverage).
Balance Sheet
Discover healthy companies
Dividend
What is Grown Rogue International current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate GRIN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate GRIN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if GRIN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if GRIN's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as GRIN has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
1.0yrs
Average management tenure
CEO
J. Strickler (42 yo)
3.67yrs
Tenure
US$174,882
Compensation
Mr. J. Obie Strickler serves as President, Chief Executive Officer and Chairman at Grown Rogue International Inc. He Co-Founded Grown Rogue International Inc. He is the Director of Grown Rogue Internationa...
CEO Compensation Analysis
Compensation vs Market: Insufficient data to establish whether J.'s total compensation is reasonable compared to companies of similar size in the Canadian market.
Compensation vs Earnings: J.'s compensation has been consistent with company performance over the past year.
Leadership Team
Experienced Management: GRIN's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Board Members
Experienced Board: GRIN's board of directors are considered experienced (3.7 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: GRIN insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 8.8%.
Top Shareholders
Company Information
Grown Rogue International Inc.'s employee growth, exchange listings and data sources
Key Information
- Name: Grown Rogue International Inc.
- Ticker: GRIN
- Exchange: CNSX
- Founded: NaN
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: CA$15.357m
- Shares outstanding: 170.63m
- Website: https://www.grownrogue.com
Location
- Grown Rogue International Inc.
- 550 Airport Road
- Medford
- Oregon
- 97504
- United States
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/07/03 00:00 |
| End of Day Share Price | 2022/06/30 00:00 |
| Earnings | 2022/04/30 |
| Annual Earnings | 2021/10/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.